High grade dysplasia of the esophagus who would undergo esophagectomy OR esophageal cancer at stage T1-T3, N0-N1 who require esophagectomy (patients with M1 disease and/or bulky lymph node involvement were excluded).
Pathological confirmation of a diagnosis of cancer or high-grade dysplasia of the esophagus by biopsy.
Computerized tomography (CT) scan of chest and abdomen within 6 weeks prior to registration
Stomach must be available for conduit
Age of 18 and over
ECOG performance status of 0-2
Creatinine less than 2 mg/dL
Patients with esophageal cancer who would be treated with neoadjuvant chemotherapy and/or radiation were eligible. If patients were registered prior to receiving neoadjuvant chemotherapy they were allowed up to 5 months to complete therapy and any restaging that was necessary before operation was performed.
The patient was considered an appropriate candidate for surgery based on preoperative clinical staging and physiological factors prior to registration as documented in the surgical plan. Pre-operative staging should include:
Endoscopic ultrasound (EUS)
Positron emission tomography (PET) scan and/or laparoscopic staging (Laparoscopic staging could be performed on the day of resection. Additional evaluation was recommended if the PET scan suggested distant metastatic disease.)
EXCLUSION CRITERIA:
Cancer extending into the stomach more than 20%
Prior anti-reflux or gastric operations
Prior right thoracotomy
Prior major neck operation other than the removal of superficial skin lesion
Source : Importé depuis le centre
Cohortes
Thérapie ou Intervention proposée
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Minimally invasive esophagectomy (MIE)
Donnée non disponible
Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Inconnu
Minimally invasive esophagectomy (MIE)
État du recrutement
unknown
Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
Données à jour depuis :
30 juin 2023
Description de l'étude
Description de l'étude
Résumé de l'étude
RATIONALE: Laparoscopic-assisted surgery and video-assisted thoracoscopy are less invasive types of surgery for esophageal cancer that may have fewer side effects and improve recovery.
PURPOSE: This phase II trial is studying how well laparoscopic-assisted surgery and video-assisted thoracoscopy work in treating patients who are undergoing esophagectomy for high-grade dysplasia of the esophagus or stage I, stage II, or stage III esophageal cancer.
Source : Importé depuis le centre
OBJECTIVES:
Determine the feasibility of performing minimally invasive esophagectomy (MIE), in terms of 30-day mortality, in patients with high-grade dysplasia of the esophagus or stage I-III esophageal cancer.
Determine the complications associated with this procedure in these patients.
Determine the rate at which conversion to open operation is required in patients undergoing this procedure.
Determine the length of the operation, duration of intensive care unit stay, and length of hospital stay in patients undergoing this procedure.
Determine feasibility and conversion rate of MIE after neoadjuvant therapy.
Assess the effectiveness of lymph node dissection by MIE by recording the total number of lymph nodes dissected.
Assess outcomes at follow-up to three years.
OUTLINE: This is a multicenter study.
Patients undergo minimally invasive esophagectomy comprising video-assisted thoracoscopy to mobilize the thoracic esophagus in combination with laparoscopy to complete the esophagectomy and a neck incision to mobilize the cervical esophagus. Mortality at 30 days is assessed.
Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
ACTUAL ACCRUAL: A total of 110 patients were accrued for this study.
Source : Importé depuis le centre
Centres participants
Sites
Centres participants
10
affichés
sur
41
centres
ADENA REGIONAL MEDICAL CENTER
Chillicothe
OHIO, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
ALEGANT HEALTH CANCER CENTER AT BERGAN MERCY MEDICAL CENTER
Omaha
NEBRASKA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
ARTHUR G. JAMES CANCER HOSPITAL AND SOLOVE RESEARCH INSTITUTE AT OHIO STATE UNIVERSITY MEDICAL CENTER
Columbus
OHIO, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
BOSTON UNIVERSITY CANCER RESEARCH CENTER
Boston
MASSACHUSETTS, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
CCOP - COLUMBUS
Columbus
OHIO, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
CCOP - MISSOURI VALLEY CANCER CONSORTIUM
Omaha
NEBRASKA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
CHAO FAMILY COMPREHENSIVE CANCER CENTER AT UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER
Orange
CALIFORNIA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
COMMUNITY HOSPITAL OF SPRINGFIELD AND CLARK COUNTY
Springfield
OHIO, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
CREIGHTON UNIVERSITY MEDICAL CENTER
Omaha
NEBRASKA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
CURTIS AND ELIZABETH ANDERSON CANCER INSTITUTE AT MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER
Savannah
GEORGIA, UNITED STATES
Recrutement local
État du recrutement:
FERMÉ
Centres participants
Source d'information
Dernière modification :
30 juin 2023
Données à jour depuis :
30 juin
Origine des données :
clinicaltrials.gov